Imaging in Percutaneous Coronary Intervention

Mohan Satish(Cardiovascular Institute of the South), George Dangas(Mount Sinai Hospital), Anastasios Roumeliotis(Cardiovascular Institute of the South), Davis Jones(Cardiovascular Institute of the South), Anton Camaj(Columbia University Irving Medical Center), Johny Nicolas(Cardiovascular Institute of the South), Saman Suleman(Donald & Barbara Zucker School of Medicine at Hofstra/Northwell), Frans Beerkens(Icahn School of Medicine at Mount Sinai), David V. Power(Cardiovascular Institute of the South), Keisuke Yasumura(Cardiovascular Institute of the South), Daniel Feldman(Cardiovascular Institute of the South)
Reviews in Cardiovascular Medicine
May 31, 2022
10.31083/j.rcm2306204
Cited by 0

Related Papers

Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial
|The Lancet|2018|775
Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial
|The Lancet|2017|734
Characterization of Myocardial Injury in Patients With COVID-19
|Journal of the American College of Cardiology|2020|429
Coronary In-Stent Restenosis
|Journal of the American College of Cardiology|2022|397
Long-Term Outcome of Percutaneous Coronary Intervention for Chronic Total Occlusions
|JACC: Cardiovascular Interventions|2011|310